Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 11/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | ESRRA | P11474 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6851927 | 1.00 | LMNA (0.48) | LMNAHSD17B10ESR1ESR2MAPT | |
| SCHEMBL5973819 | 0.89 | LMNA (0.49) | LMNAHSD17B10ESR1MAPTHSD17B1 | |
| SCHEMBL5973822 | 0.89 | LMNA (0.49) | LMNAHSD17B10ESR1MAPTHSD17B1 | |
| SCHEMBL6462441 | 0.87 | LMNA (0.62) | LMNAHSD17B10ESR1ESR2MAPT | |
| SCHEMBL6840976 | 0.87 | LMNA (0.62) | LMNAHSD17B10ESR1ESR2MAPT | |
| SCHEMBL6853658 | 0.85 | LMNA (0.46) | LMNAHSD17B10ESR1ESR2MAPT | |
| SCHEMBL6853652 | 0.85 | LMNA (0.46) | LMNAHSD17B10ESR1ESR2MAPT | |
| SCHEMBL5166260 | 0.80 | LMNA (0.71) | LMNAHSD17B10ESR1ESR2MAPT | |
| SCHEMBL11672711 | 0.80 | LMNA (0.71) | LMNAHSD17B10ESR1ESR2MAPT | |
| SCHEMBL11860032 | 0.80 | LMNA (0.71) | LMNAHSD17B10ESR1ESR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780854-B2 | MALE CONTRACEPTION | AKZO NOBEL NV (NL) | 2004-08-24 | — | — | US | disclosed |
| EP-1203011-B1 | ORALLY ACTIVE ANDROGENS | AKZO NOBEL NV (NL) | 2004-01-02 | — | — | EP | disclosed |
| US-6541465-B2 | Delta 14 derivatives of 19- nortestosterone, useful for the preparation of a medicine for treating androgen insufficiency | AKZO NOBEL N.V. (NL) | 2003-04-01 | — | — | US | disclosed |
| EP-1203011-A1 | ORALLY ACTIVE ANDROGENS | Akzo Nobel N.V. (NL) | 2002-05-08 | — | — | EP | disclosed |
| US-20020022609-A1 | Orally active androgens | LOOZEN HUBERT JAN JOZEF (NL) | 2002-02-21 | — | — | US | disclosed |
| US-6313108-B1 | TREATING ANDROGEN INSUFFICIENCY | AKZO NOBEL N.V. (NL) | 2001-11-06 | — | — | US | disclosed |
| WO-2001005806-A1 | ORALLY ACTIVE ANDROGENS | AKZO NOBEL N.V. (NL) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022609-A1 | Orally active androgens | NR5A1, AR, CYP17A1 | LMNA 2728/4885HSD17B10 41/4885ESR1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.